companies / abcuro-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-13 json
| total_raised | 300,000,000300.0M | ○ |
|---|---|---|
| founded | 2018 | |
| hq | Newton | |
| industry | unknown | |
| stage | series-b+ |
Abcuro develops monoclonal antibodies that selectively deplete highly cytotoxic T and NK cells driving autoimmune disease and cancer. It targets patients with conditions such as inclusion body myositis and T/NK-cell lymphomas. Its lead antibody ulviprubart, now in late-stage trials, is built around precise KLRG1 targeting.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2025-02-12 | series-c | 200,000,000200.0M | null | ○ |
| investor | src |
|---|---|
| New Enterprise Associates | ○ |
PHP 7.4.33, WordPress 5.9.3, Apache HTTP Server, Yoast SEO 18.2, Genesis theme, jQuery Migrate 3.3.2, MySQL, jquery 3.6.0, apache
| fact | status | src |
|---|---|---|
| Series C, $200.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-27latest_round: series-c, $200.0M, 2025-02-12, lead: nea → series-c, $200.0M, 2025-02-12, lead: null, ○ 2026-05-13 | latest_round | series-c, $200.0M, 2025-02-12, lead: nea → series-c, $200.0M, 2025-02-12, lead: null | ○ 2026-05-13 |
Records begin 2026-09-24. all_changes